UNSPSC 51372206: Dextromoramide bitartrate

This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J778U505W5, chemically known as (+)-4-(2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl)butyl)morpholine bitartrate, but more generally known as dextromoramide bitartrate, which bears US NIH Compound Identifier 92942. European Medicines Agency schedules dextromoramide bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07052MIG.

Most nations, for tariff purposes, schedule dextromoramide bitartrate under HS 29349100. SMILES: C[C@H](CN1CCOCC1)C(C2CCCCC2)(C3CCCCC3)C(=O)N4CCCC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51372206 Dextromoramide bitartrate is a Commodity code that in practice encompasses pharmaceutical procurement across state and local health and human services operations — though recent state and local solicitations tagged to this code show little direct activity in dextromoramide itself and instead reflect broader pharmaceutical supply agreements. The actual buying activity under related pharmaceutical codes involves opioid antagonists (naloxone), over-the-counter medications, and generic multi-source drugs procured by county health departments, state HHS agencies, and cooperative purchasing alliances. Issuing bodies include county health systems (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, serving participating states including Oregon). The scope spans routine pharmaceutical supply for community health initiatives, pharmacy benefit program direct-to-manufacturer arrangements, and bulk generic and OTC product agreements distributed through authorized wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023 (note: date inconsistency in source), with quarterly deliveries to the county community health building and fixed-fee pricing. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with no award values or formal evaluation timelines specified at the information-gathering stage. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring cGMP and Drug Supply Chain Security Act compliance, pricing through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson), and a two-year contract term effective July 1, 2026 with 75 percent weight on price competitiveness.